
Novo Nordisk inks $2-billion obesity drug deal with United Labs
Novo Nordisk A/S agreed to pay United Laboratories International Holdings as much as $2 billion for a next-generation obesity drug, the Danish Ozempic maker's latest move to refill its pipeline of experimental treatments. Novo will pay Hong Kong- …